GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CervoMed Inc (NAS:CRVO) » Definitions » 9-Day RSI

CRVO (CervoMed) 9-Day RSI : 20.85 (As of Dec. 13, 2024)


View and export this data going back to 1996. Start your Free Trial

What is CervoMed 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-13), CervoMed's 9-Day RSI is 20.85.

The industry rank for CervoMed's 9-Day RSI or its related term are showing as below:

CRVO's 9-Day RSI is ranked better than
95.93% of 1524 companies
in the Biotechnology industry
Industry Median: 44.945 vs CRVO: 20.85

Competitive Comparison of CervoMed's 9-Day RSI

For the Biotechnology subindustry, CervoMed's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CervoMed's 9-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CervoMed's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where CervoMed's 9-Day RSI falls into.



CervoMed  (NAS:CRVO) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CervoMed  (NAS:CRVO) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


CervoMed 9-Day RSI Related Terms

Thank you for viewing the detailed overview of CervoMed's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


CervoMed Business Description

Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02116
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Executives
William Robert Elder officer: GC & Secretary 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Sylvie Gregoire director, 10 percent owner 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
John William Tanner officer: Chief Financial Officer C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116
Frank Zavrl director C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Kelly Blackburn officer: VP, Clinical Development C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jeffrey V. Poulton director 300 THIRD STREET, CAMBRIDGE MA 02142
John J Alam director, 10 percent owner, officer: CEO and President 130 WAVERLY STREET, CAMBRIDGE MA 02139
Jill Davidson director 300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902
Raven Jaeger officer: Chief Regulatory Officer 300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902
Eric Francois director C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Diana M Lanchoney director 1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902
Cobuzzi Robert Joseph Jr. director C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Christopher D Galloway officer: Chief Medical Officer 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902
Jane H Hollingsworth director DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902